Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant trastuzumab + pertuzumab + taxane vs trastuzumab emtansine + pertuzumab after anthracyclines in operable HER2-positive breast cancer
jRCT2080222371Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of trastuzumab emtansine, pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Invasive disease-free survival (IDFS). Started Jan 2014; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222371.